microRNA-122在肝病发生发展及诊断中的作用

陈泽山; 文彬; 丘佩容; 蓝红妮; 黄宝特; 邓鑫

doi:10.3969/j.issn.1001-5256.2021.07.052

microRNA-122在肝病发生发展及诊断中的作用

DOI: 10.3969/j.issn.1001-5256.2021.07.052

陈泽山¹,
文彬^2a,
丘佩容¹,
蓝红妮³,
黄宝特^2b,
邓鑫^2c, ,

1.
广西中医药大学研究生学院, 南宁 530001
2a.
广西中医药大学附属瑞康医院感染科, 南宁 530001
2b.
广西中医药大学附属瑞康医院科技处, 南宁 530001
2c.
广西中医药大学附属瑞康医院消化内科, 南宁 530001
3.
广西中医药大学第一附属医院内分泌科, 南宁 530001

基金项目:

国家自然科学基金 (81860790);

广西自然科学基金项目 (2017GXNSFAA198183)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：陈泽山负责课题设计, 资料分析, 撰写论文, 修改论文; 文彬、丘佩容、蓝红妮、黄宝特参与文献数据的收集及分析; 邓鑫负责拟定写作思路, 指导撰写文章并最后定稿。

详细信息

通信作者:
邓鑫, dx8849@163.com

中图分类号: R575
计量
- 文章访问数: 685
- HTML全文浏览量: 185
- PDF下载量: 78
- 被引次数: 0
出版历程
- 收稿日期: 2020-12-03
- 录用日期: 2020-12-25
- 出版日期: 2021-07-20

Role of microRNA-122 in the development, progression, and diagnosis of liver disease

1.
Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, China
2a.
Department of Infectious Diseases, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China
2b.
Department of Science and Technology, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China
2c.
Department of Gastroenterology, Ruikang Hospital, Guangxi University of Chinese Medicine, Nanning 530001, China
3.
Department of Endocrinology, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530001, China

Research funding:

National Natural Science Foundation of China (81860790);

Guangxi Natural Science Foundation of China (2017GXNSFAA198183)

摘要

摘要: microRNA(miRNA)是一类小分子非编码RNA, 转录后通过调控基因表达参与细胞增殖和凋亡等多个环节。目前越来越多的证据表明miRNA-122参与了多种肝病的发生、发展, 通过查阅相关文献报道, 总结了miRNA-122在非酒精性脂肪性肝病、肝炎、肝纤维化、肝癌等多种肝病中作用的研究进展, 同时分析了miRNA-122作为一种新型无创的生物学标志物的潜能, 为探索肝脏疾病诊疗提供参考。
- 肝疾病 /
- 微RNAs /
- 诊断
Abstract: MicroRNA is a type of small non-coding RNA that participates in multiple links such as cell proliferation and apoptosis by regulating gene expression after transcription. More and more studies have shown that microRNA-122 (miRNA-122) is involved in the development and progression of a variety of liver diseases. With reference to related reports in the literature, this article summarizes advances in the role of miRNA-122 in various liver diseases including nonalcoholic fatty liver disease, hepatitis, liver fibrosis, and liver cancer and analyzes the potential of miRNA-122 as a new noninvasive biomarker, so as to provide a reference for exploring the diagnosis and treatment of liver disease.
- Liver Diseases /
- MicroRNAs /
- Diagnosis

HTML全文

参考文献(53)

[1]	MATSUYAMA H, SUZUKI HI. Systems and synthetic microRNA biology: From biogenesis to disease pathogenesis[J]. Int J Mol Sci, 2019, 21(1): 132. DOI: 10.3390/ijms21010132.
[2]	ZHAO Y, WANG Z, ZHANG W, et al. MicroRNAs play an essential role in autophagy regulation in various disease phenotypes[J]. Biofactors, 2019, 45(6): 844-856. DOI: 10.1002/biof.1555.
[3]	LEE RC, FEINBAUM RL, AMBROS V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14[J]. Cell, 1993, 75(5): 843-854. DOI: 10.1016/0092-8674(93)90529-y.
[4]	FIRE A, XU S, MONTGOMERY MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391(6669): 806-811. DOI: 10.1038/35888.
[5]	LAGOS-QUINTANA M, RAUHUT R, LENDECKEL W, et al. Identification of novel genes coding for small expressed RNAs[J]. Science, 2001, 294(5543): 853-858. DOI: 10.1126/science.1064921.
[6]	KOZOMARA A, GRIFFITHS-JONES S. miRBase: Annotating high confidence microRNAs using deep sequencing data[J]. Nucleic Acids Res, 2014, 42(Database issue): d68-d73. DOI: 10.1093/nar/gkt1181.
[7]	LAGOS-QUINTANA M, RAUHUT R, YALCIN A, et al. Identification of tissue-specific microRNAs from mouse[J]. Curr Biol, 2002, 12(9): 735-739. DOI: 10.1016/s0960-9822(02)00809-6.
[8]	YOUNOSSI ZM. Non-alcoholic fatty liver disease - A global public health perspective[J]. J Hepatol, 2019, 70(3): 531-544. DOI: 10.1016/j.jhep.2018.10.033.
[9]	YAMADA H, SUZUKI K, ICHINO N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver[J]. Clin Chim Acta, 2013, 424: 99-103. DOI: 10.1016/j.cca.2013.05.021.
[10]	LONG JK, DAI W, ZHENG YW, et al. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease[J]. Mol Med, 2019, 25(1): 26. DOI: 10.1186/s10020-019-0085-2.
[11]	PURUSHOTHAM A, SCHUG TT, XU Q, et al. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation[J]. Cell Metab, 2009, 9(4): 327-338. DOI: 10.1016/j.cmet.2009.02.006.
[12]	LI X. SIRT1 and energy metabolism[J]. Acta Biochim Biophys Sin(Shanghai), 2013, 45(1): 51-60. DOI: 10.1093/abbs/gms108.
[13]	WANG S, QIU L, YAN X, et al. Loss of microRNA 122 expression in patients with hepatitis B enhances hepatitis B virus replication through cyclin G(1)-modulated P53 activity[J]. Hepatology, 2012, 55(3): 730-741. DOI: 10.1002/hep.24809.
[14]	QU JH, ZHU MH, LIN J, et al. Effects of hepatitis B virus on p53 expression in hepatoma cell line SMMU-7721[J]. World J Gastroenterol, 2005, 11(39): 6212-6215. DOI: 10.3748/wjg.v11.i39.6212.
[15]	CHEN Y, SHEN A, RIDER PJ, et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication[J]. FASEB J, 2011, 25(12): 4511-4521. DOI: 10.1096/fj.11-187781.
[16]	XU H, XU SJ, XIE SJ, et al. MicroRNA-122 supports robust innate immunity in hepatocytes by targeting the RTKs/STAT3 signaling pathway[J]. Elife, 2019, 8. DOI: 10.7554/eLife.41159.
[17]	WACK A, TERCZYŃSKA-DYLA E, HARTMANN R. Guarding the frontiers: The biology of type Ⅲ interferons[J]. Nat Immunol, 2015, 16(8): 802-809. DOI: 10.1038/ni.3212.
[18]	LI XD, SUN L, SETH RB, et al. Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity[J]. Proc Natl Acad Sci U S A, 2005, 102(49): 17717-17722. DOI: 10.1073/pnas.0508531102.
[19]	GERRESHEIM GK, DVNNES N, NIEDER-RÖHRMANN A, et al. microRNA-122 target sites in the hepatitis C virus RNA NS5B coding region and 3' untranslated region: Function in replication and influence of RNA secondary structure[J]. Cell Mol Life Sci, 2017, 74(4): 747-760. DOI: 10.1007/s00018-016-2377-9.
[20]	HE YJ, HUANG ML, LE Y, et al. Effect of myricitrin on replication of hepatitis C virus through microRNA-122[J]. Pharmacol Clin Chin Materia Med, 2020, 36(4): 99-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202004019.htm 何玉娇, 黄茂林, 乐燕, 等. 杨梅苷通过microRNA-122对丙型肝炎病毒复制的影响[J]. 中药药理与临床, 2020, 36(4): 99-102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYYL202004019.htm
[21]	KATAREY D, VERMA S. Drug-induced liver injury[J]. Clin Med (Lond), 2016, 16(Suppl 6): s104-s109. DOI: 10.7861/clinmedicine.16-6-s104.
[22]	LI LN, LI Y, PENG JY. microRNA and drug-induced liver injury[J]. Chin J Clin Pharmacol Ther, 2020, 25(7): 803-809. DOI: 10.12092/j.issn.1009-2501.2020.07.013. 许丽娜, 李月, 彭金咏. microRNA与药物性肝损伤[J]. 中国临床药理学与治疗学, 2020, 25(7): 803-809. DOI: 10.12092/j.issn.1009-2501.2020.07.013.
[23]	CHOWDHARY V, TENG KY, THAKRAL S, et al. miRNA-122 protects mice and human hepatocytes from acetaminophen toxicity by regulating cytochrome P450 family 1 subfamily a member 2 and family 2 subfamily E member 1 expression[J]. Am J Pathol, 2017, 187(12): 2758-2774. DOI: 10.1016/j.ajpath.2017.08.026.
[24]	Liver Disease Committee, Chinese Association of Integrative Medicine. Guidelines for the diagnosis and treatment of liver fibrosis with integrated traditional Chinese and Western medicine (2019 edition)[J]. J Clin Hepatol, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007. 中国中西医结合学会肝病专业委员会. 肝纤维化中西医结合诊疗指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(7): 1444-1449. DOI: 10.3969/j.issn.1001-5256.2019.07.007.
[25]	YANG AT, HU DD, WANG P, et al. TGF-β1 induces the dual regulation of hepatic progenitor cells with both anti- and proliver fibrosis[J]. Stem Cells Int, 2016, 2016: 1492694. DOI: 10.1155/2016/1492694.
[26]	LI JH, HUANG XR, ZHU HJ, et al. Role of TGF-beta signaling in extracellular matrix production under high glucose conditions[J]. Kidney Int, 2003, 63(6): 2010-2019. DOI: 10.1046/j.1523-1755.2003.00016.x.
[27]	CHENG B, ZHU Q, LIN W, et al. MicroRNA-122 inhibits epithelial-mesenchymal transition of hepatic stellate cells induced by the TGF-β1/Smad signaling pathway[J]. Exp Ther Med, 2019, 17(1): 284-290. DOI: 10.3892/etm.2018.6962.
[28]	WANG SC, LIN XL, LI J, et al. MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA[J]. PLoS One, 2014, 9(7): e101330. DOI: 10.1371/journal.pone.0101330.
[29]	CSAK T, BALA S, LIPPAI D, et al. microRNA-122 regulates hypoxia-inducible factor-1 and vimentin in hepatocytes and correlates with fibrosis in diet-induced steatohepatitis[J]. Liver Int, 2015, 35(2): 532-541. DOI: 10.1111/liv.12633.
[30]	LU SC, AKANJI AO. Leptin, obesity, and hypertension: A review of pathogenetic mechanisms[J]. Metab Syndr Relat Disord, 2020, 18(9): 399-405. DOI: 10.1089/met.2020.0065.
[31]	BENBAIBECHE H, BOUNIHI A, KOCEIR EA. Leptin level as a biomarker of uncontrolled eating in obesity and overweight[J]. Ir J Med Sci, 2021, 190(1): 155-161. DOI: 10.1007/s11845-020-02316-1.
[32]	DUAN DM, JHANG JY, WU S, et al. Modification effect of sex and obesity on the correlation of LEP polymorphisms with leptin levels in Taiwanese obese women[J]. Mol Genet Genomic Med, 2020, 8(3): e1113. DOI: 10.1002/mgg3.1113.
[33]	CAO Q, ZHU X, ZHAI X, et al. Leptin suppresses microRNA-122 promoter activity by phosphorylation of FOXO1 in hepatic stellate cell contributing to leptin promotion of mouse liver fibrosis[J]. Toxicol Appl Pharmacol, 2018, 339: 143-150. DOI: 10.1016/j.taap.2017.12.007.
[34]	MATTIUZZI C, LIPPI G. Current cancer epidemiology[J]. J Epidemiol Glob Health, 2019, 9(4): 217-222. DOI: 10.2991/jegh.k.191008.001.
[35]	SZABO G, BALA S. MicroRNAs in liver disease[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(9): 542-552. DOI: 10.1038/nrgastro.2013.87.
[36]	YAHYA S, FATHY SA, EL-KHAYAT ZA, et al. Possible role of microRNA-122 in modulating multidrug resistance of hepatocellular carcinoma[J]. Indian J Clin Biochem, 2018, 33(1): 21-30. DOI: 10.1007/s12291-017-0651-8.
[37]	BAI S, NASSER MW, WANG B, et al. MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib[J]. J Biol Chem, 2009, 284(46): 32015-32027. DOI: 10.1074/jbc.M109.016774.
[38]	YANG G, ZHANG M, ZHAO Y, et al. HNF-4α inhibits hepatocellular carcinoma cell proliferation through miR-122-adam17 pathway[J]. PLoS One, 2020, 15(3): e0230450. DOI: 10.1371/journal.pone.0230450.
[39]	ZHANG S, LIN YH, TARLOW B, et al. The origins and functions of hepatic polyploidy[J]. Cell Cycle, 2019, 18(12): 1302-1315. DOI: 10.1080/15384101.2019.1618123.
[40]	MARGALL-DUCOS G, CELTON-MORIZUR S, COUTON D, et al. Liver tetraploidization is controlled by a new process of incomplete cytokinesis[J]. J Cell Sci, 2007, 120(Pt 20): 3633-3639. DOI: 10.1242/jcs.016907.
[41]	GUIDOTTI JE, BRÉGERIE O, ROBERT A, et al. Liver cell polyploidization: A pivotal role for binuclear hepatocytes[J]. J Biol Chem, 2003, 278(21): 19095-19101. DOI: 10.1074/jbc.M300982200.
[42]	DONNE R, SAROUL-AÏNAMA M, CORDIER P, et al. Polyploidy in liver development, homeostasis and disease[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(7): 391-405. DOI: 10.1038/s41575-020-0284-x.
[43]	ZHANG S, ZHOU K, LUO X, et al. The polyploid state plays a tumor-suppressive role in the liver[J]. Dev Cell, 2018, 47(3): 390. DOI: 10.1016/j.devcel.2018.10.020.
[44]	LIN YH, ZHANG S, ZHU M, et al. Mice with increased numbers of polyploid hepatocytes maintain regenerative capacity but develop fewer hepatocellular carcinomas following chronic liver injury[J]. Gastroenterology, 2020, 158(6): 1698-1712.e14. DOI: 10.1053/j.gastro.2020.01.026.
[45]	HSU SH, DELGADO ER, OTERO PA, et al. MicroRNA-122 regulates polyploidization in the murine liver[J]. Hepatology, 2016, 64(2): 599-615. DOI: 10.1002/hep.28573.
[46]	GUO BH, WU DD, KUANG YL. SF, 25-OH Vit D and miR-122 levels in patients with NAFLD expression and clinical significance[J]. Chin Foreign Med Res, 2020, 18(6): 153-156. DOI: 10.14033/j.cnki.cfmr.2020.06.065. 郭笔红, 吴丹丹, 邝燕玲. SF、25-OH Vit D及miR-122水平在NAFLD患者中表达及临床意义[J]. 中外医学研究, 2020, 18(6): 153-156. DOI: 10.14033/j.cnki.cfmr.2020.06.065.
[47]	OMRAN AA, OSMAN KS, KAMEL HM, et al. MicroRNA-122 as a novel non-invasive marker of liver fibrosis in hepatitis C virus patients[J]. Clin Lab, 2016, 62(7): 1329-1337. DOI: 10.7754/Clin.Lab.2015.151141.
[48]	WANG K, ZHANG S, MARZOLF B, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury[J]. Proc Natl Acad Sci U S A, 2009, 106(11): 4402-4407. DOI: 10.1073/pnas.0813371106.
[49]	MCGILL MR, SHARPE MR, WILLIAMS CD, et al. The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation[J]. J Clin Invest, 2012, 122(4): 1574-1583. DOI: 10.1172/JCI59755.
[50]	ANTOINE DJ, DEAR JW, LEWIS PS, et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital[J]. Hepatology, 2013, 58(2): 777-787. DOI: 10.1002/hep.26294.
[51]	DEAR JW, CLARKE JI, FRANCIS B, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: Results from two prospective cohort studies[J]. Lancet Gastroenterol Hepatol, 2018, 3(2): 104-113. DOI: 10.1016/S2468-1253(17)30266-2.
[52]	FRANCK M, SCHÁTTE K, MALFERTHEINER P, et al. Prognostic value of serum microRNA-122 in hepatocellular carcinoma is dependent on coexisting clinical and laboratory factor[J]. World J Gastroenterol, 2020, 26(1): 86-96. DOI: 10.3748/wjg.v26.i1.86.
[53]	ZHAO XF, LI N, LIN DD, et al. Circulating microRNA-122 for the diagnosis of hepatocellular carcinoma: A meta-analysis[J]. Biomed Res Int, 2020, 2020: 5353695. DOI: 10.1155/2020/5353695.